digiM is a technology leader supporting drug product development with end-to-end microstructure CRO and software solutions. digiM’s I2S cloud software integrates AI image processing, microstructural analysis, digital formulation, image-based simulation, and data management to support the lifecycle of advanced microscopy data analysis. I2S modules are custom built to address the most critical questions and attributes of pharmaceutical materials. Through integration of microscopy-based digital twins and in silico modelling, the digiM platform provides a full spectrum understanding of drug product properties and performance.
digiM works closely with leading innovators and generic developers to navigate development challenges, having supported over 100 pharmaceutical partners, 200 therapeutic programs, and 1,600 drug intermediates and products. digiM works closely with regulatory bodies, including the FDA, paving an advanced understanding for the role microstructures play in product quality, while also bridging the gap between industry and regulatory agencies.